Biocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...

The Guidance Document establishes, for the first time, a structured and standardised national framework for the screening, diagnosis, treat...

Over the next few sessions, as the uncertainty caused by the Gulf war intensifies and makes you anxious, remember this: It is not the first...

A new weight-loss drug, retatrutide, is generating excitement. This investigational medicine targets three hormone receptors, offering a po...

Biocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management...

Cipla has launched a new orally inhaled insulin powder for diabetes patients in India. This needle-free alternative to injections offers a ...

Hope is on the horizon for Type-1 diabetes patients. New stem cell therapies are showing remarkable progress. These treatments aim to repla...

Type 1 diabetes is a chronic autoimmune condition. It affects millions in the US. The body's immune system destroys insulin-producing cells...

Biocon will strengthen its insulin business while advancing in GLP-1 therapies, with semaglutide in Phase-III trials and a planned 2027 Ind...

Biocon share price jumped after its subsidiary Biocon Biologics received USFDA approval for Kirsty, a rapid-acting insulin biosimilar. This...

Novo Nordisk will discontinue Human Mixtard, a top-selling insulin in India. This decision aligns with the company's global strategy. They ...

Chinese scientists achieve diabetes cure through innovative cell therapy, detailed in Cell Discovery. Patient, treated in July 2021, no lon...

However, improper choice of injection site, technique including reuse of needles might lead to compromised outcomes.

A pill could circumvent the discomfort associated with the needle while potentially providing a more effective dose, the researchers said.

Newer and more expensive categories of insulin are being aggressively "pushed" by drug companies, and, hence, increasingly prescribed.

Nutech Mediworld has developed a Human Embryonic Stem Cell (HESC) therapy which will go a long way in treating patients with type-II diabet...

Current treatments for type I diabetes focus on controlling blood sugar with insulin therapy and must continue throughout a person's life.